Back to Authors

Barbu, Sorin T.

https://orcid.org/0000-0001-8058-2554

Mayo Clinic

Iuliu Hațieganu University of Medicine and Pharmacy

Citations 2

Mortality in acute pancreatitis with persistent organ failure is determined by the number, type, and sequence of organ systems affected
Machicado, Jorge D. , Gougol, Amir , Tan, Xiaoqing , Gao, Xiaotian , Pothoulakis, Ioannis , Talukdar, Rupjyoti , Gulla, Aistė , Stevens, Tyler , Barbu, Sorin T. , Nawaz, Haq , Gutierrez, Silvia C., Zarnescu, Narcis , Capurso, Gabriele , Easler, Jeffrey J. , Τriantafyllou, Κonstantinos , Thakkar, Shyam , Ocampo, Carlos , de‐Madaria, Enrique , Coté, Gregory A. , Conwell, Darwin L. , Hart, Phil A. , Tang, Gong , Pothoulakis, Ioannis , de-Madaria, Enrique , Paragomi, Pedram , Kochhar, Rakesh K. , Goenka, Mahesh Kumar , González, José Alberto , Singh, Vikesh K. , Ferreira, Miguel Godinho , Peláez‐Luna, Mario , Wu, Bechien U. , Papachristou, Georgios I.

United European Gastroenterology Journal | April 19, 2021 | Volume: 9 | Issue: 2 | Pages: 139-149

10.1002/ueg2.12057 Get It

Abstract Background Persistent organ failure (POF) is the strongest determinant of mortality in acute pancreatitis (AP). There is a paucity of data regarding the impact of different POF attributes on mortality and the role of different characteristics of systemic inflammatory response syndrome (SIRS) in the risk of developing POF. Objective We aimed to assess the association of POF dynamic features with mortality and SIRS characteristics with POF. Methods We studied 1544 AP subjects prospectively enrolled at 22 international centers (APPRENTICE consortium). First, we estimated the association of onset, duration, and maximal score of SIRS with POF. Then, we evaluated the risk of mortality based on POF onset, duration, number, type, and sequence of organs affected. Analyses were adjusted for potential confounders. Results 58% had SIRS, 11% developed POF, and 2.5% died. Early SIRS, persistent SIRS, and maximal SIRS score ≥ 3 were independently associated with higher risk of POF ( p < 0.05). Mortality risk in POF was higher with two (33%, odds ratio [OR] = 10.8, 3.3–34.9) and three (48%, OR = 20.2, 5.9–68.6) organs failing, in comparison to single POF (4%). In subjects with multiple POF, mortality was higher when the cardiovascular and respiratory systems failed first or concurrently as compared to when the renal system failed first or concurrently with other organ ( p < 0.05). In multivariate regression model, the number and sequence of organs affected in POF were associated with mortality ( p < 0.05). Onset and duration of POF had no impact mortality. Conclusion In AP patients with POF, the risk of mortality is influenced by the number, type, and sequence of organs affected. These results are useful for future revisions of AP severity classification systems.
Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study
de‐Madaria, Enrique , Sánchez‐Marin, Claudia , Carrillo, Irene , Vege, Santhi Swaroop , Chooklin, Serge , Bilyak, Andriy , Mejuto, Rafael , Mauriz, Violeta, Hegyi, Péter , Márta, Katalin , Kamal, Ayesha , Lauret-Braña, Eugenia, Barbu, Sorin T. , Nunes, Vítor , Ruiz-Rebollo, María Lourdes, García‐Rayado, Guillermo , Hernández, Edgard Efrén Lozada , Pereira, Jorge , Negoi, Ionuţ , Espina, Silvia , Hollenbach, Marcus , Litvin, Andrey , Bolado, Federico , Pascual, Isabel , de-Madaria, Enrique , Vargas, Rómulo , Singh, Vikesh K. , Mira, José Joaquín

Gut | April 3, 2020 | Volume: 70 | Issue: 1 | Pages: 139-147

10.1136/gutjnl-2020-320729 Get It

Objective This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. Design A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. Results PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test–retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. Conclusion The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up. Trial registration number NCT03650062